Barclays PLC Ovid Therapeutics Inc. Transaction History

Barclays PLC

$854 Billion
Q3 2025

A detailed history of Barclays PLC transactions in Ovid Therapeutics Inc. stock. As of the latest transaction made, Barclays PLC holds 71 shares of OVID stock, worth $93. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 71 -0.0%

Holding current value

$93

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	SELL	$0.26 - $0.35 $16,600 - $22,346	-63,847 Reduced 99.89%	71 $0
Q1 2025 May 15, 2025	SELL	$0.31 - $0.96 $9,110 - $28,213	-29,389 Reduced 31.5%	63,918 $19,000
Q4 2024 Feb 13, 2025	BUY	$0.93 - $1.36 $8,492 - $12,419	9,132 Added 10.85%	93,307 $87,000
Q3 2024 Nov 15, 2024	BUY	$0.75 - $1.3 $47,776 - $82,812	63,702 Added 311.15%	84,175 $98,000
Q2 2024 Aug 14, 2024	SELL	$0.7 - $3.34 $15,164 - $72,354	-21,663 Reduced 51.41%	20,473 $15,000

Q1 2024 May 15, 2024	SELL	$2.72 - $4.04 $108,593 - $161,292	-39,924 Reduced 48.65%	42,136 $128,000
Q4 2023 Feb 15, 2024	BUY	$2.98 - $3.78 $212,414 - $269,438	71,280 Added 661.22%	82,060 $264,000
Q3 2023 Nov 07, 2023	SELL	$3.23 - $3.97 $3,795 - $4,664	-1,175 Reduced 9.83%	10,780 $41,000
Q2 2023 Aug 03, 2023	BUY	$2.53 - $3.89 $30,246 - $46,504	11,955 New	11,955 $40,000
Q4 2021 Feb 14, 2022	SELL	$3.13 - $3.73 $25,722 - $30,653	-8,218 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$3.31 - $4.04 $89,399 - $109,116	-27,009 Reduced 76.67%	8,218 $28,000
Q2 2021 Aug 13, 2021	SELL	$3.3 - $4.49 $16,005 - $21,776	-4,850 Reduced 12.1%	35,227 $137,000
Q1 2021 May 13, 2021	BUY	$2.42 - $4.47 $59,817 - $110,489	24,718 Added 160.93%	40,077 $161,000
Q4 2020 Feb 11, 2021	SELL	$2.28 - $6.84 $23,429 - $70,287	-10,276 Reduced 40.09%	15,359 $35,000
Q3 2020 Nov 12, 2020	BUY	$5.39 - $8.24 $11,108 - $16,982	2,061 Added 8.74%	25,635 $147,000
Q2 2020 Aug 12, 2020	BUY	$2.67 - $7.91 $62,942 - $186,470	23,574 New	23,574 $173,000
Q3 2019 Nov 14, 2019	SELL	$1.76 - $3.51 $469 - $937	-267 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$1.59 - $2.14 $5,495 - $7,395	-3,456 Reduced 92.83%	267 $0
Q1 2019 May 15, 2019	BUY	$1.77 - $3.56 $6,589 - $13,253	3,723 New	3,723 $7,000
Q4 2018 Feb 14, 2019	SELL	$2.42 - $6.6 $11,949 - $32,590	-4,938 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$5.6 - $11.0 $19,700 - $38,698	3,518 Added 247.75%	4,938 $28,000
Q2 2018 Aug 14, 2018	SELL	$6.16 - $10.14 $6,886 - $11,336	-1,118 Reduced 44.05%	1,420 $11,000
Q1 2018 May 15, 2018	BUY	$6.53 - $9.82 $11,342 - $17,057	1,737 Added 216.85%	2,538 $18,000
Q4 2017 Feb 14, 2018	BUY	$6.12 - $12.31 $4,179 - $8,407	683 Added 578.81%	801 $8,000
Q3 2017 Nov 14, 2017	BUY	$5.32 - $9.77 $627 - $1,152	118	118 $1,000

Others Institutions Holding OVID

# of Institutions

Shares Held

33.1M

Call Options Held

141K

Put Options Held

62.5K

View Full List

About Ovid Therapeutics Inc.

Ticker OVID
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,419,400
Market Cap $92.2M
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...

More about OVID

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account